Apic Bio gathers $40 mln Series A

Cambridge, Massachusetts-based Apic Bio Inc, a gene therapy company developing novel treatment options for patients with rare genetic diseases, has closed $40 million in Series A financing. Morningside Venture Investments Ltd led the round with participation from The Alpha-1 Project, A1ATD Investors LLC and ALS Investment Fund.

Source: Press Release